Mezagitamab

迈泽妥单抗

Report date: 2026/04/14 20:00:15

Base Information

Drug NameMezagitamab
Drug Alias NameTAK-079
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnti-CD38
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicThrombocytopenia +[10
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[34
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicThrombocytopeniaPurpura, Thrombocytopenic, Idiopathic +[9
Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A